HOME › DRUGS › VOXELOTOR
ACTIVE SUBSTANCE / INN

VOXELOTOR

Brand name(s): OXBRYTA, Oxbryta
FDA LISTED
EMA LISTED
SUSPENDED
DISCONTINUED
Anemia;Anemia, Hemolytic;Anemia, Sickle Cell
NDA216157
ACTIVE SUBSTANCE
Voxelotor
REGULATORS
FDA · EMA
SPONSORS / MAH
GLOBAL BLOOD THERAPS, Pfizer Europe MA EEIG
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
OXBRYTANDA216157GLOBAL BLOOD THERAPSDiscontinued
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
OxbrytaPfizer Europe MA EEIGSuspended14/02/2022Anemia;Anemia, Hemolytic;Anemia, Sickle Cell

FULL INTELLIGENCE ON VOXELOTOR

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →